Drawing for INITIAL STATE (OIL SEPRATE FROM WATER) SHAKING/MIXING MIXED STATE (CLOUDY, OIL MIXED WITH WATER) SETTLED STATE (OIL SEPARATED FROM WATER)

USPTO serial 88391059

INITIAL STATE (OIL SEPRATE FROM WATER) SHAKING/MIXING MIXED STATE (CLOUDY, OIL MIXED WITH WATER) SETTLED STATE (OIL SEPARATED FROM WATER)

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
BEN, LINDSEY HEATHER
Law office
TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with INITIAL STATE (OIL SEPRATE FROM WATER) SHAKING/MIXING MIXED STATE (CLOUDY, OIL MIXED WITH WATER) SETTLED STATE (OIL SEPARATED FROM WATER)?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
003Fragrances; Fragrances and perfumery; Body spray used as a personal deodorant and as fragrance; Pet fragrancesPARTIALLY PAIDDec 7, 2017
005Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Anti-epileptic pharmaceutical preparations; Antibacterial pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents in the form of a coating for agents in solution that facilitate the delivery of a wide range of pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of integumentary conditions; Homeopathic pharmaceuticals for use in the treatment of musculoskeletal conditions; Homeopathic pharmaceuticals for use in the treatment of immune conditions; Homeopathic pharmaceuticals for use in the treatment of neurologic conditions; Homeopathic pharmaceuticals for use in the treatment of digestive conditions; Homeopathic pharmaceuticals for use in the treatment of endocrine conditions; Homeopathic pharmaceuticals for use in the treatment of bacterial infections; Homeopathic pharmaceuticals for use in the treatment of fungal infectionsPARTIALLY PAIDDec 7, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Oct 21, 2020MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 21, 2020ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 9, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 9, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 9, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 8, 2020RFTPREMOVED FROM TEAS PLUS—
Apr 1, 2020DOCKASSIGNED TO EXAMINER—
Jun 26, 2019DOCKASSIGNED TO EXAMINER—
Jun 19, 2019DOCKASSIGNED TO EXAMINER—
May 17, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 16, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 22, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance